Tau[P301L] model
Take advantage of InnoSer’s expanded neurology CRO services spanning new Alzheimer’s in vivo research models and expertise
Key characteristics
- Progressive hyperphosphorylation and conformational change of Tau
- Neurofibrillary tangles are mainly observed in the brain stem, spinal cord and midbrain and to lesser extent in the cerebral cortex
- Astrocytosis, microgliosis and neuronal loss in regions with Tau pathology
- Cognitive impairment in passive avoidance paradigm and LTP deficit from 5 months of age
- Correlation of motoric impairment and survival with Tau hyperphosphorylation
- Correlation of motoric impairment with spinal cord pathology
Age dependent increase of Tau pathology (AT8 = pSer202 pThr205 Tau, AT100 = pThr212/pSer214 Tau) in the interposed cerebellar nulceis, anterior and posterior part (LAT/Int/AP) as measured by IHC (mean ± SEM, n = 15). Statistics: One-way ANOVA.
Progressive neuronal loss (NeuN) in the subthalamic nucleus and zona inserta (STH/ZI, n = 14, 15 and 28 respectively), as measured by IHC. Statistics: Two-way ANOVA, Tukey’s multiple comparison
Progressive astrocytosis (GFAP) and microgliosis correlates with Tau pathology in the interposed cerebellar nulceis, anterior and posterior part (LAT/Int/AP) as measured by IHC (mean ± SEM, n = 14, 15 and 28 respectively). The correlation graphs are only for 9.3 months of age. Statistics: Two-Way ANOVA, Tukey’s multiple comparison
Literature
Describing papers:
- Original paper: Terwel et al., 2005: Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. DOI: 10.1074/jbc.M409876200
- Chong et al., 2011: Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer’s disease: A multi-electrode array study. DOI: 10.1016/j.nbd.2011.07.006
Therapeutic intervention papers:
- Bright et al. 2015: Human secreted tau increases amyloid-beta production. DOI: 10.1016/j.neurobiolaging.2014.09.007
- Hansen et al. 2016: The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. DOI: 10.1016/j.brainres.2015.12.052
- Theunis et al. 2013: Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy. DOI: 10.1371/journal.pone.0072301
- Pre-clinical data is listed in the iPierian patent WO 2014/028777
Services
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
Elevate Your Research With Additional Services
Readouts & Analyses
- Full suite of histopathology services
- Immunohistochemistry of brain and nerve tissues (IHC)
- Bioanalyses in various biological matrices
- Flow Cytometry
- ELISA, Ultra-Sensitive ELISA for CSF/plasma biomarkers
- Meso Scale Discovery (MSD)
- Immunoblotting
In Vivo Analyses
- Mouse breeding and genotyping
- Microbiome transplantation studies
- Compound administration
- Stereotaxic surgery
- EEG, EMG and ECG analyses
- Cannula implantation
- Tissue collection and analysis
Stay Curious: More Articles to Explore
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com